Cargando…

Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker

BACKGROUND: Alterations in lipid metabolism promote tumor progression. However, the role of lipid metabolism in the occurrence and development of gastric cancer have not been fully clarified METHOD: Here, genes that are related to fatty acid metabolism and differentially-expressed between normal and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shifeng, Sun, Boshi, Li, Wenjing, Yang, Hao, Li, Nana, Zhang, Xinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797045/
https://www.ncbi.nlm.nih.gov/pubmed/36591293
http://dx.doi.org/10.3389/fimmu.2022.1065927
_version_ 1784860616343683072
author Yang, Shifeng
Sun, Boshi
Li, Wenjing
Yang, Hao
Li, Nana
Zhang, Xinyu
author_facet Yang, Shifeng
Sun, Boshi
Li, Wenjing
Yang, Hao
Li, Nana
Zhang, Xinyu
author_sort Yang, Shifeng
collection PubMed
description BACKGROUND: Alterations in lipid metabolism promote tumor progression. However, the role of lipid metabolism in the occurrence and development of gastric cancer have not been fully clarified METHOD: Here, genes that are related to fatty acid metabolism and differentially-expressed between normal and gastric cancer tissues were identified in the TCGA-STAD cohort. The intersection of identified differentially-expressed genes with Geneset was determined to obtain 78 fatty acid metabolism-related genes. The ConsensusClusterPlus R package was used to perform differentially-expressed genes, which yielded divided two gastric cancer subtypes termed cluster 1 and cluster 2. RESULTS: Patients in cluster 2 was found to display poorer prognosis than patients in cluster 1. Using machine learning method to select 8 differentially expressed genes among subtypes to construct fatty acid prognostic risk score model (FARS), which was found to display good prognostic efficacy. We also identified that certain anticancer drugs, such as bortezomib, elesclomol, GW843682X, and nilotinib, showed significant sensitivity in the high FARS score group. RGS2 was selected as the core gene upon an analysis of the gastric cancer single-cell, and Western blotting and immunofluorescence staining results revealed high level of expression of this gene in gastric cancer cells. The results of immunohistochemical staining showed that a large amount of RGS2 was deposited in the stroma in gastric cancer. A pan-cancer analysis also revealed a significant association of RGS2 with TMB, TIDE, and CD8+ T-cell infiltration in other cancer types as well. RGS2 may thus be studied further as a new target for immunotherapy in future studies on gastric cancer. CONCLUSION: In summary, the FARS model developed here enhances our understanding of lipid metabolism in the TME in gastric cancer, and provides a theoretical basis for predicting tumor prognosis and clinical treatment.
format Online
Article
Text
id pubmed-9797045
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97970452022-12-29 Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker Yang, Shifeng Sun, Boshi Li, Wenjing Yang, Hao Li, Nana Zhang, Xinyu Front Immunol Immunology BACKGROUND: Alterations in lipid metabolism promote tumor progression. However, the role of lipid metabolism in the occurrence and development of gastric cancer have not been fully clarified METHOD: Here, genes that are related to fatty acid metabolism and differentially-expressed between normal and gastric cancer tissues were identified in the TCGA-STAD cohort. The intersection of identified differentially-expressed genes with Geneset was determined to obtain 78 fatty acid metabolism-related genes. The ConsensusClusterPlus R package was used to perform differentially-expressed genes, which yielded divided two gastric cancer subtypes termed cluster 1 and cluster 2. RESULTS: Patients in cluster 2 was found to display poorer prognosis than patients in cluster 1. Using machine learning method to select 8 differentially expressed genes among subtypes to construct fatty acid prognostic risk score model (FARS), which was found to display good prognostic efficacy. We also identified that certain anticancer drugs, such as bortezomib, elesclomol, GW843682X, and nilotinib, showed significant sensitivity in the high FARS score group. RGS2 was selected as the core gene upon an analysis of the gastric cancer single-cell, and Western blotting and immunofluorescence staining results revealed high level of expression of this gene in gastric cancer cells. The results of immunohistochemical staining showed that a large amount of RGS2 was deposited in the stroma in gastric cancer. A pan-cancer analysis also revealed a significant association of RGS2 with TMB, TIDE, and CD8+ T-cell infiltration in other cancer types as well. RGS2 may thus be studied further as a new target for immunotherapy in future studies on gastric cancer. CONCLUSION: In summary, the FARS model developed here enhances our understanding of lipid metabolism in the TME in gastric cancer, and provides a theoretical basis for predicting tumor prognosis and clinical treatment. Frontiers Media S.A. 2022-12-14 /pmc/articles/PMC9797045/ /pubmed/36591293 http://dx.doi.org/10.3389/fimmu.2022.1065927 Text en Copyright © 2022 Yang, Sun, Li, Yang, Li and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yang, Shifeng
Sun, Boshi
Li, Wenjing
Yang, Hao
Li, Nana
Zhang, Xinyu
Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker
title Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker
title_full Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker
title_fullStr Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker
title_full_unstemmed Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker
title_short Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker
title_sort fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and rgs2 is a new tumor biomarker
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797045/
https://www.ncbi.nlm.nih.gov/pubmed/36591293
http://dx.doi.org/10.3389/fimmu.2022.1065927
work_keys_str_mv AT yangshifeng fattyacidmetabolismisrelatedtotheimmunemicroenvironmentchangesofgastriccancerandrgs2isanewtumorbiomarker
AT sunboshi fattyacidmetabolismisrelatedtotheimmunemicroenvironmentchangesofgastriccancerandrgs2isanewtumorbiomarker
AT liwenjing fattyacidmetabolismisrelatedtotheimmunemicroenvironmentchangesofgastriccancerandrgs2isanewtumorbiomarker
AT yanghao fattyacidmetabolismisrelatedtotheimmunemicroenvironmentchangesofgastriccancerandrgs2isanewtumorbiomarker
AT linana fattyacidmetabolismisrelatedtotheimmunemicroenvironmentchangesofgastriccancerandrgs2isanewtumorbiomarker
AT zhangxinyu fattyacidmetabolismisrelatedtotheimmunemicroenvironmentchangesofgastriccancerandrgs2isanewtumorbiomarker